Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial.

Biweekly Methotrexate and Vinblastine: A New Oasis in Desmoid Fibromatosis Treatment

In the vast and often unforgiving desert of desmoid-type fibromatosis (DF) treatment, researchers are constantly searching for new and effective therapies. This study, like a caravan venturing into uncharted territory, evaluated the efficacy of biweekly administration of methotrexate (MTX) and vinblastine (VBL) chemotherapy in a cohort of patients with refractory DF. The researchers aimed to determine if a biweekly regimen could achieve similar clinical outcomes to the previously established weekly regimen.

A New Route: Biweekly Chemotherapy Shows Promising Results

The study found that biweekly administration of low-dose MTX and VBL was well-tolerated and showed similar efficacy to the weekly regimen, achieving a partial response (PR) in 51% of patients and a clinical benefit rate of 95%. The progression-free survival (PFS) at 5 years was 80.8%, demonstrating the long-term effectiveness of this treatment approach. While a longer duration of therapy was associated with a higher response rate, the study did not find a clear association between various clinicopathological factors, including tumor size, location, and CTNNB1 mutation status.

A New Oasis for Desmoid Fibromatosis Patients

This study provides a valuable contribution to the treatment of DF, offering a less frequent and potentially more convenient chemotherapy regimen. The biweekly administration of MTX and VBL could be a welcome oasis for patients with refractory DF, potentially improving their quality of life and treatment outcomes.

Dr.Camel's Conclusion

This study, like a caravan bringing life-saving supplies to a thirsty desert community, provides a new and potentially more convenient option for treating desmoid fibromatosis. The biweekly regimen of MTX and VBL offers a glimmer of hope for patients battling this challenging condition.